yukon choice pc ® sirolimus eluting coronary stent system with a biodegradable polymer
TRANSCRIPT
![Page 1: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/1.jpg)
YUKON Choice PC®
Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer
![Page 2: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/2.jpg)
Technology HighlightsYUKON Choice PC is manufactured by Translumina Therapeutics in their manufacturing Facility at Pharma City Dehradun. Its a collaboration between Advance Therapeutics and Translumina GmbH, Germany.
• This is the first project where a proven technology of a drug Eluting Stent is sourced from Europe and is manufactured in India using international standards .
• The technology is proven in large trials in Europe but shall be sourced from India for world.
• For the first time, High end machines and layout are created as per the specifications of European guidelines.
![Page 3: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/3.jpg)
Translumina GmbH-Germany
• Founded in 1998 ,The promoters were in Senior Management positions in Guidant(Now abott) and Boston Scientific.
• The company is based at Hechingen ,Germany with state of the art manufacturing facility.
• Translumina was the first company to launch a Drug Eluting Stent without a polymer,YUKON Choice, using a innovative technology of in-cath lab coating in 2003 .
• Translumina is marketing its products in India for the last 6 years.All the raw materials for Indian manufacturing shall be provided by Translumina GmbH
![Page 4: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/4.jpg)
• YUKON Choice PC is a combination of : - Sirolimus - Microporous Stent surface - Biodegradable Polymer Resomer R202S - Shellac Resin
• YUKON Choice PC is a third generation Sirolimus eluting Stent System that combines the synergistic effect of surface modification and biodegradable polymer to create optimum release.
• YUKON Choice PC’s Stent surface is coated
abluminally with no drug or polymer on the luminal side of the Stent for enhanced safety.
![Page 5: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/5.jpg)
YUKON Choice PC - A generation ahead
less polymeric load compared to other DES
• YUKON Choice PC® has microporous surface which enables minimum load of a biodegradable Polymer for optimizing the release kinetics
• Micro-pores which act like reservoirs for delivering the drug to the targeted sites use Van-der-Waals forces to control the release- kinetics of the drug
![Page 6: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/6.jpg)
YUKON Choice PC - Safety Features
• Better Endothelialization-No coating on the Luminal side of the Stent • Biodegradable Polymer-Degrades in 90 days• Less Polymeric Load-1/4th of the polymeric load compared to other DES
![Page 7: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/7.jpg)
Release Kinetics
Drug and Polymer are co-released in 30-45 days
![Page 8: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/8.jpg)
YUKON Choice PC - Efficacy Vs. Xience & Cypher
ISAR-TEST 4 is the first prospective randomized trial which compares 3 DES i.e.YUKON Choice PC, Xience and Cypher for their efficacy & safety
![Page 9: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/9.jpg)
YUKON Choice PCISAR-TEST 4 is the only trial with planned angiographic follow up at 2 years in more than 70% patients
![Page 10: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/10.jpg)
ISAR-TEST 4 - ResultsYUKON Choice PC proves non-inferior to Xience and Cypher at 3 years follow up published in JACC Sept. 2011
![Page 11: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/11.jpg)
ISAR-TEST 4 - ResultsYUKON Choice PC proves non-inferior to Xience and Cypher at 3 years follow up published in JACC Sept. 2011
![Page 12: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/12.jpg)
ISAR-TEST 4 - ResultsYUKON Choice PC shows similar TLR’s compared to Xience and Cypher at 2 years follow up
![Page 13: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/13.jpg)
ISAR-TEST 4 - AMI Sub-groupYUKON Choice PC has least polymeric load of a biodegradable polymer and thus is hypothesized to how better results than Xience and Cypher
![Page 14: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/14.jpg)
ISAR-TEST 4 - AMI Sub-groupYUKON Choice PC shows better results than Xience and Cypher in AMI patients
![Page 15: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/15.jpg)
Yukon Choice PC 4 years follow-up data compared to first generation DES
![Page 16: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/16.jpg)
ISAR-TEST 4 - 3 years follow-upISAR-TEST 4 is the only comparative trial of 3 DES, YUKON Choice PC Xience and Cypher, with 3 years follow-up
![Page 17: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/17.jpg)
ISAR-TEST 4 - Study Flow
![Page 18: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/18.jpg)
ISAR-TEST 4 - Results
YUKON Choice PC is the First DES which has shown statistical significant reduction of Stent Thrombosis by 50% compared to first generation DES.
![Page 19: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/19.jpg)
ISAR-TEST 4 - Results
YUKON Choice PC shows 78% reduction in Stent Thrombosis compared to first generation DES.
![Page 20: YUKON Choice PC ® Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer](https://reader036.vdocument.in/reader036/viewer/2022062308/56649daa5503460f94a9806d/html5/thumbnails/20.jpg)
YUKON Choice PC - Excellent Safety Profile• YUKON Choice PC is the First DES which has shown statistical significant reduction in Stent thrombosis compared to first generation DES.
• YUKON Choice PC shows 78% reduction in Stent Thrombosis compared to first generation DES.
• The unique combination of microporous Stent surface and less biodegradable polymeric load ensures that it becomes a BMS after the drug delivery.
• The presence of drug only on the abluminal side ensures healthy endothelialization.
• Limited anti-platelet regimen may be required after implantation.